These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29547977)

  • 21. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study.
    Crank CW; Scheetz MH; Brielmaier B; Rose WE; Patel GP; Ritchie DJ; Segreti J
    Clin Ther; 2010 Sep; 32(10):1713-9. PubMed ID: 21194593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients.
    Gallagher JC; Perez ME; Marino EA; LoCastro LG; Abrardo LA; MacDougall C
    Pharmacotherapy; 2009 Jul; 29(7):792-9. PubMed ID: 19558253
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of daptomycin doses on the outcomes of VRE bloodstream infection treated with high-dose daptomycin.
    Chuang YC; Lin HY; Yang JL; Lin CY; Huang SH; Wang JT; Chen YC; Chang SC
    J Antimicrob Chemother; 2022 Jul; 77(8):2278-2287. PubMed ID: 35639586
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emergence of daptomycin non-susceptibility in colonizing vancomycin-resistant Enterococcus faecium isolates during daptomycin therapy.
    Lellek H; Franke GC; Ruckert C; Wolters M; Wolschke C; Christner M; Büttner H; Alawi M; Kröger N; Rohde H
    Int J Med Microbiol; 2015 Dec; 305(8):902-9. PubMed ID: 26454536
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of daptomycin dose and fosfomycin susceptibility on outcome of vancomycin-resistant Enterococcus faecium bloodstream infections treated with daptomycin and fosfomycin combination.
    Chuang YC; Tseng TC; Wang JT; Lin CY; Huang SH; Chen YC; Chang SC
    J Antimicrob Chemother; 2022 Apr; 77(5):1436-1443. PubMed ID: 35141753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: Towards a common nomenclature.
    Bender JK; Cattoir V; Hegstad K; Sadowy E; Coque TM; Westh H; Hammerum AM; Schaffer K; Burns K; Murchan S; Novais C; Freitas AR; Peixe L; Del Grosso M; Pantosti A; Werner G
    Drug Resist Updat; 2018 Sep; 40():25-39. PubMed ID: 30447411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment options for serious infections caused by vancomycin-resistant enterococci].
    Mutters NT; Werner G; Tacconelli E; Mischnik A
    Dtsch Med Wochenschr; 2015 Jan; 140(1):42-5. PubMed ID: 25580973
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Daptomycin.
    Enoch DA; Bygott JM; Daly ML; Karas JA
    J Infect; 2007 Sep; 55(3):205-13. PubMed ID: 17629567
    [TBL] [Abstract][Full Text] [Related]  

  • 29. E. faecalis vancomycin-sensitive enterococcal bacteremia unresponsive to a vancomycin tolerant strain successfully treated with high-dose daptomycin.
    Cunha BA; Mickail N; Eisenstein L
    Heart Lung; 2007; 36(6):456-61. PubMed ID: 18005808
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of risk factors and outcomes of daptomycin-susceptible and -nonsusceptible vancomycin-resistant Enterococcus faecium infections in liver transplant recipients.
    Lewis JD; Barros AJ; Sifri CD
    Transpl Infect Dis; 2018 Jun; 20(3):e12856. PubMed ID: 29427322
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors.
    Chow A; Win NN; Ng PY; Lee W; Win MK
    Epidemiol Infect; 2016 Sep; 144(12):2540-5. PubMed ID: 27174845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Time-kill curves of daptomycin and Monte Carlo simulation for the treatment of bacteraemia caused by Enterococcus faecium.
    Menezes BK; Alves IA; Staudt KJ; Beltrame BM; Venz L; Michelin L; Araujo BV; Tasso L
    Braz J Microbiol; 2020 Mar; 51(1):169-176. PubMed ID: 31845296
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    Aktas G
    Microb Drug Resist; 2019 Dec; 25(10):1484-1489. PubMed ID: 31343391
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
    Kullar R; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
    Pharmacotherapy; 2011 Jun; 31(6):527-36. PubMed ID: 21923436
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of daptomycin versus linezolid treatment in patients with vancomycin-resistant enterococcal bacteraemia: An updated systematic review and meta-analysis.
    Shi C; Jin W; Xie Y; Zhou D; Xu S; Li Q; Lin N
    J Glob Antimicrob Resist; 2020 Jun; 21():235-245. PubMed ID: 31629937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Daptomycin for endocarditis and/or bacteraemia: a systematic review of the experimental and clinical evidence.
    Falagas ME; Giannopoulou KP; Ntziora F; Vardakas KZ
    J Antimicrob Chemother; 2007 Jul; 60(1):7-19. PubMed ID: 17550889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vancomycin-resistant Enterococcus bacteremia in a child with acute myeloid leukemia: successful treatment with daptomycin.
    Büyükcam A; Karadağ Öncel E; Özsürekçi Y; Cengiz AB; Kuşkonmaz B; Sancak B
    Arch Argent Pediatr; 2016 Dec; 114(6):e432-e435. PubMed ID: 27869427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment options for vancomycin-resistant enterococcal infections.
    Linden PK
    Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.
    Cairns KA; Udy AA; Peel TN; Abbott IJ; Dooley MJ; Peleg AY
    Clin Microbiol Rev; 2023 Jun; 36(2):e0005922. PubMed ID: 37067406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Editorial Commentary: Linezolid vs Daptomycin for Vancomycin-Resistant Enterococci: The Evidence Gap Between Trials and Clinical Experience.
    McKinnell JA; Arias CA
    Clin Infect Dis; 2015 Sep; 61(6):879-82. PubMed ID: 26063714
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.